A detailed history of Parallel Advisors, LLC transactions in Geron Corp stock. As of the latest transaction made, Parallel Advisors, LLC holds 287 shares of GERN stock, worth $1,050. This represents 0.0% of its overall portfolio holdings.

Number of Shares
287
Previous 277 3.61%
Holding current value
$1,050
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$4.17 - $4.99 $41 - $49
10 Added 3.61%
287 $1,000
Q2 2024

Aug 08, 2024

BUY
$3.1 - $5.09 $406 - $666
131 Added 89.73%
277 $1,000
Q2 2022

Aug 01, 2022

SELL
$1.19 - $1.65 $1,135 - $1,574
-954 Reduced 86.73%
146 $0
Q2 2021

Aug 06, 2021

BUY
$1.25 - $1.83 $1,375 - $2,013
1,100 New
1,100 $2,000
Q4 2019

Jan 30, 2020

SELL
$1.27 - $1.54 $1,587 - $1,925
-1,250 Closed
0 $0
Q1 2018

May 08, 2018

BUY
$1.81 - $5.98 $2,262 - $7,475
1,250 New
1,250 $5,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.38B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.